Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-03-22
2011-03-22
Aeder, Sean E (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07910295
ABSTRACT:
The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and β-HCG.
REFERENCES:
patent: 6057105 (2000-05-01), Hoon et al.
patent: 6248535 (2001-06-01), Danenberg et al.
patent: 6331393 (2001-12-01), Laird et al.
patent: 6428963 (2002-08-01), Danenberg et al.
patent: 6518416 (2003-02-01), Danenberg
patent: 6573052 (2003-06-01), Danenberg
patent: 6602670 (2003-08-01), Danenberg
patent: 6610488 (2003-08-01), Danenberg et al.
patent: 6613518 (2003-09-01), Danenberg et al.
patent: 2001/0029018 (2001-10-01), Danenberg et al.
patent: 0 520 794 (1992-06-01), None
patent: 96/29430 (1996-09-01), None
patent: WO 99/10528 (1999-03-01), None
patent: WO 02/70571 (2002-03-01), None
patent: 2004/045521 (2004-06-01), None
Kuo et al (Feb. 1998, Clinical Cancer Research, 4:411-418).
Palmieri et al (Mar. 2001, Journal of Clinical Oncology, 19(5):1437-1443).
Scholl et al (Feb. 2001, Cancer Research, 61:823-826).
Koyanagi et al (2005) J Clin Oncol 23(31):8057-8064.
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Koyanagi et al (J Clin Oncol, 2005, 23(31):8057-8064).
Johansson et al (2000, Clinical Chemistry, 46(7): 921-927).
Hatta et al (Melanoma Research, Aug. 1999, 9(4): abstract).
Scoggins et al (Journal of Clinical Oncology, 2006, 24(18): 2849-2857).
Mocellin et al (TRENDS in Molecular Medicine, 2003, 9(5):189-195).
Tsao et al (Arch Dermatol, 2001, 137:325-330).
Gerber et al (Journal of Clinical Oncology, 2001, 19(4): 960-971).
Hilari et al (Ann Surg Oncol, 2009, 16(1): 177-185).
Tatilidil et al (Modern Pathology, 2007, 20: 427-434).
Denninghoff et al (Mol Diag, 2004, 8(4): Abstract).
Hoon et al (J Clin Oncol, 1995, 13(18): 2109-2116).
Scoggins et al (Journal of Clinical Oncology, 2006, 24(16):2849-2856).
Hillari et al (Ann Surg Oncol, 2009, 16:177-185).
Kuo et al (Clinical Cancer Research, 1998, 4(411-418).
Morton, D. L., Wen, D. R., Wong, J. H., Economou, J. S., Cagle, L. A., Storm, F. K., et al. Techinical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392-399, 1992.
Li W, Stall A, Shivers SC, Lin J, Haddad F, Messina J, et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of paients with melanoma. Ann Surg 2000;231:795-803.
Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, Kuo CK, Foshag LJ, Nizze JA., Morton DL. Detection o occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J. Clin. Oncol., 13: 2109-16, 1995.
Morton DL, Wen DR, Foshag LJ, Essner R, Cochran A. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol 1993;11:1751-6.
Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-63.
Taback B, Morton DL, O'Day SJ, Nguyen Dh, Nakayama T, Hoon DS. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. Recent Results. Cancer Res 2001;158:78-92.
Sarantou, T., Chi, D. D. J., Garrison, D. A., Conrad, A.J., Schmid, P. Morton, D. L., and Hoon D. S. B. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res., 57: 1371-1376, 1997.
Bostick, P. J., Morton, D. L., Turner, R. R., Huynh K. T., Wang, H-J., Elashoff R., Essner R., and Hoon, D. S. B Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J. Clin. Oncol, 17: 3238-3244, 1999.
Hoon D. S. B, Bostick P., Kuo, C., Okamoto T, Wang H-J., Elashoff, R., and Morton, D. L. Molecular markers in blood a surrogate prognostic indicators of melanoma recurrence. Cancer Res., 60: 2253-2257, 2000.
Miyashiro, I., Kuo, C., Huynh, K., Iida A., Morton D., Bilchik, A., Giuliano A., and Hoon D. S. B. Molecular strategy fo detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin. Chem. 47: 505-512, 2001.
Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K. Analysis of chemical modification of RNA from formalin-fix samples and optimization of molecular biology applications for such samples. Nuc Acid Res 1999;27:4436-43.
Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298 304.
Hoon DS, Banez M, Okun E, Morton DL, Irie RF. Modulation of human melanoma cells by interleukin-4 and in combination with γ-interferon or α-tumor necrosis factor. Cancer Res 1991;51:2002-8.
Tai T, Paulson JC, Cahan LD, Irie RF. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci US 1983;80:5392-6.
Kuo CT, Bostick PJ, Irie RF, Morton DL, Conrad AJ, Hoon DS. Assessment of messenger RNA of β 1→4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma. Clin Cancer Res 1998;4:411-8.
Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996;46:225-44.
O'Day SJ, Boasberg PD, Piro L, Kristedja TS, et al. Maintenance biotherapy for metastatic melanoma with interleukin 2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cance Res 2002;8:2775-81.
Henderson AR. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann Clin Biochem 1993;30:521-29.
Mitas M, Mikhitarian K, Walters C, et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer 2001;93:162-71.
Bilchik, A. J., Saha, S., Wiese, D., Stonecypher, J. A., Wood, T. F., Sostrin, S., Turner, R. R., Wang, H-J., Morton D. L., and Hoon, D. S. B Molecular staging of early colon cancer on the basis of sentinel node analysis: A multicenter phase I trial. J. Clin. Oncol, 19: 1128-1136, 2001.
Bilchek et al., “Molecular Detection of Metastatic Pancreatic Carcinoma Cells Using a Multimarker Reverse Transcriptase-Polymerase Chain Reaction Assay”. Cancer. 88:1037-1044 (2000).
Supplementary European Search Report (SESR).
Kocher et al., “Identification of Genes Differentially Expressed in Melanoma Sublines Derived from a Single Surgical Specimen Characterized by Different Sensitivity to Cytotoxic T-Iymphocyte Activity,” Dept. of Surgery, Z.L.F., pp. 617-624.
Vachtenheim et al., “Expression of Genes for Microphthalmia Isoforms, PAX3 and MSG1, in Human Melanomas,” Cellular and Molecular Biology, vol. 45, pp. 1075-1082 (1999).
Balch et al., “Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma,” J. Clin. Oncol., 19: 3635-48, 2001.
Balch et al., “New TNM Melanoma Staging System: Linking Biology and Natural History to Clinical Outcomes,” Semin. Surgical Oncology, 21: 43-52, 2003.
Bostick et al., “Limitations of Specific Reverse-Transcriptase Polymerase Chain Reaction Markers in the Detection of Metastases in the Lymph Nodes and Blood of Breast Cancer Patients,” J. Clinical Oncol., 16: 2632-40, 1998.
Bouras et al., “
Hoon Dave S. B.
Takeuchi Hiroya
Aeder Sean E
Brooks & Kushman P.C.
John Wayne Cancer Institute
LandOfFree
Detection of micro metastasis of melanoma and breast cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection of micro metastasis of melanoma and breast cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection of micro metastasis of melanoma and breast cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2663068